Biophan's Nanolution Division to Present at Nanomaterials 2004 Conference.

ROCHESTER, N.Y. -- Nanolution President John Lanzafame to Provide Overview of Biophan's Nanoengineered Biomedical Solutions

Nanolution, a Division of Biophan Technologies, Inc. (OTCBB:BIPH), will present at the "Nanomaterials 2004: Emphasizing Biotechnology and Biomedicine" conference, held today in Stamford, CT. The announcement was made by Michael Weiner, CEO of Biophan.

The Nanomaterials conference, organized by Business Communications Company, Inc., a leading nanotechnology market research firm, will feature presentations from an international group of participants that represent the research, business, and investment communities. Nanolution president, John Lanzafame, will present an overview of the Company's next-generation nanotechnology solutions for drug delivery and drug elution from device surfaces.

"Gatherings such as the BCC Nanomaterials 2004 Conference are one of the best tools we have for exchanging information with our colleagues in the research and investment communities, as well as meeting with prospective partners and existing customers," said Mr. Lanzafame. "We look forward to discussing Biophan's exciting developments, innovative solutions, and the work going on elsewhere in our industry."

Presentations at the BCC Nanomaterials 2004 Conference will focus on nanobiotechnology and nanomedicine.

About Business Communications Company, Inc.

Business Communications Company, Inc. is a nanotechnology-oriented market research firm that has been tracking new developments in nanomaterials and nanotechnology for nearly 10 years. It follows all nanomaterial and nanotechnology topics, including nanocomposites, nanotubes, quantum dots, and biotechnology. The firm's nanotechnology experts have over 20 years of experience in the field. They publish reports and newsletters, and organize conferences that cover the latest developments in processing technologies, industry professionals, technology transfer, government funding, relevant patents, research advancements, industry news, and market data.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan product lines include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors have 21 issued U.S. patents and 71 patents pending, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.